Group II metabotropic glutamate receptors modify N-methyl-D-aspartate receptors via Src kinase

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Trepanier, Catherine ^a   Lei, Gang ^b   Xie, Yu Feng ^b   MacDonald, John F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYLASPARTIC ACID; PROTEIN TYROSINE KINASE;

ANIMAL; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; HIPPOCAMPUS; IN VITRO STUDY; METABOLISM; PATCH CLAMP; PHYSIOLOGY; RAT; SYNAPSE; WISTAR RAT;

ADENYLATE CYCLASE; ANIMALS; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HIPPOCAMPUS; N-METHYLASPARTATE; PATCH-CLAMP TECHNIQUES; RATS; RATS, WISTAR; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; SRC-FAMILY KINASES; SYNAPSES;

MLCS; MLOWN;

EID: 84881406051     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00926     Document Type: Article

References (48)

1. Tsai, G. & Coyle, J. T. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42, 165-179 (2002).
2. Pilowsky, L. S. et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry 11, 118-119 (2006).
3. Hahn, C. G. et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 12, 824-828 (2006).
4. Krystal, J. H. et al. Subanesthetic effects of the noncompetitive NMD Aantagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51, 199-214 (1994).
5. Javitt, D. C. & Zukin, S. R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148, 1301-1308 (1991).
6. Harrison, P. J. & Weinberger, D. R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10, 40-68; image 45 (2005).
7. Imre, G. The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268. CNS Drug Rev 13, 444-464 (2007).
8. Patil, S. T. et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13, 1102-1107 (2007).
9. Moghaddam, B. & Adams, B. W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281, 1349-1352 (1998).
10. Galici, R., Echemendia, N. G., Rodriguez, A. L. & Conn, P. J. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 315, 1181-1187 (2005).
11. Olszewski, R. T. et al. Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. Biol Psychiatry 63, 86-91 (2008).
12. Crook, J. M., Akil, M., Law, B. C., Hyde, T. M. & Kleinman, J. E. Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects. Mol Psychiatry 7, 157-164 (2002).
13. Wright, R. A. et al. CNS distribution of metabotropic glutamate 2 and 3 receptors: Transgenic mice and [(3)H]LY459477 autoradiography. Neuropharmacology (2012).
14. Niswender, C. M. & Conn, P. J. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 50, 295-322 (2010).
15. Anwyl, R. Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res Brain Res Rev 29, 83-120 (1999).
16. Manahan-Vaughan, D. Group 1 and 2 metabotropic glutamate receptors play differential roles in hippocampal long-term depression and long-term potentiation in freely moving rats. J Neurosci 17, 3303-3311 (1997).
17. Weinberger, D. R., Berman, K. F., Suddath, R. & Torrey, E. F. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J Psychiatry 149, 890-897 (1992).
18. Marsh, L., Suddath, R. L., Higgins, N. & Weinberger, D. R. Medial temporal lobe structures in schizophrenia: relationship of size to duration of illness. Schizophr Res 11, 225-238 (1994).
19. Lu, W. Y. et al. G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors. Nat Neurosci 2, 331-338 (1999).
20. Kotecha, S. A. et al. Co-stimulation of mGluR5 and N-methyl-D-aspartate receptors is required for potentiation of excitatory synaptic transmission in hippocampal neurons. J Biol Chem 278, 27742-27749 (2003).
21. MacDonald, J. F., Kotecha, S. A., Lu, W. Y. & Jackson, M. F. Convergence of PKCdependent kinase signal cascades on NMDA receptors. Curr Drug Targets 2, 299-312 (2001).
22. Macdonald, D. S. et al. Modulation of NMDA receptors by pituitary adenylate cyclase activating peptide in CA1 neurons requires G alpha q, protein kinase C, and activation of Src. J Neurosci 25, 11374-11384 (2005).
23. Yang, K. et al. Metaplasticity gated through differential regulation of GluN2A versus GluN2B receptors by Src family kinases. EMBO J (2011).
24. Monn, J. A. et al. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (1)22-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem 42, 1027-1040 (1999).
25. Skeberdis, V. A. et al. Protein kinase A regulates calcium permeability of NMDA receptors. Nat Neurosci 9, 501-510 (2006).
26. Gingrich, J. R. et al. Unique domain anchoring of Src to synaptic NMD Areceptors via the mitochondrial protein NADH dehydrogenase subunit 2. Proc Natl Acad Sci U S A 101, 6237-6242 (2004).
27. Smart, J. E. et al. Characterization of sites for tyrosine phosphorylation in the transforming protein of Rous sarcoma virus (pp60v-src) and its normal cellular homologue (pp60c-src). Proc Natl Acad Sci U S A 78, 6013-6017 (1981).
28. Cheng, S. H. et al. Structural elements that regulate pp59c-fyn catalytic activity, transforming potential, and ability to associate with polyomavirus middle-T antigen. J Virol 65, 170-179 (1991).
29. Paoletti, P., Ascher, P. & Neyton, J. High-affinity zinc inhibition of NMDA NR1-NR2A receptors. J Neurosci 17, 5711-5725 (1997).
30. Nada, S., Okada, M., MacAuley, A., Cooper, J. A. & Nakagawa, H. Cloning of a complementary DNA for a protein-tyrosine kinase that specifically phosphorylates a negative regulatory site of p60c-src. Nature 351, 69-72 (1991).
31. Vang, T. et al. Activation of the COOH-terminal Src kinase (Csk) by cAMPdependent protein kinase inhibits signaling through the T cell receptor. J Exp Med 193, 497-507 (2001).
32. Liu, X. et al. Regulation of c-Src tyrosine kinase activity by the Src SH2 domain. Oncogene 8, 1119-1126 (1993).
33. Roussel, R. R., Brodeur, S. R., Shalloway, D. & Laudano, A. P. Selective binding of activated pp60c-src by an immobilized synthetic phosphopeptide modeled on the carboxyl terminus of pp60c-src. Proc Natl Acad SciU S A 88, 10696-10700 (1991).
34. Heidinger, V. et al. Metabotropic glutamate receptor 1-induced upregulation of NMDA receptor current: mediation through the Pyk2/Src-family kinase pathway in cortical neurons. J Neurosci 22, 5452-5461 (2002).
35. Abrahamsen, H., Vang, T. & Taskén, K. Protein kinase A intersects SRC signaling in membrane microdomains. J Biol Chem 278, 17170-17177 (2003).
36. Ma, Y. C., Huang, J., Ali, S., Lowry, W. & Huang, X. Y. Src tyrosine kinase is a novel direct effector of G proteins. Cell 102, 635-646 (2000).
37. Della Rocca, G. J. et al. Ras-dependent mitogen-activated protein kinase activation by G protein-coupled receptors. Convergence of Gi- and Gq-mediated pathways on calcium/calmodulin, Pyk2, and Src kinase. J Biol Chem 272, 19125-19132 (1997).
38. Luttrell, L. M. et al. Role of c-Src tyrosine kinase in G protein-coupled receptorand Gbetagamma subunit-mediated activation of mitogen-activated protein kinases. J Biol Chem 271, 19443-19450 (1996).
39. Farazifard, R. & Wu, S. H. Metabotropic glutamate receptors modulate glutamatergic and GABAergic synaptic transmission in the central nucleus of the inferior colliculus. Brain Res 1325, 28-40 (2010).
40. Poisik, O. et al. Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus. Neuropharmacology 49 Suppl 1, 57-69 (2005).
41. Le Meur, K., Galante, M., Angulo, M. C. & Audinat, E. Tonic activation of NMDA receptors by ambient glutamate of non-synaptic origin in the rat hippocampus. J Physiol 580, 373-383 (2007).
42. Gao, X. M. et al. Ionotropic glutamate receptors and expression of N-methyl-Daspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry 157, 1141-1149 (2000).
43. Gu, Z., Jiang, Q., Fu, A. K., Ip, N. Y. & Yan, Z. Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex. J Neurosci 25, 4974-4984 (2005).
44. Pitcher, G. M. et al. Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors. Nat Med 17, 470-478 (2011).
45. Wittmann, M., Marino, M. J., Henze, D. A., Seabrook, G. R. & Conn, P. J. Clozapine potentiation of N-methyl-D-aspartate receptor currents in the nucleus accumbens: role of NR2B and protein kinase A/Src kinases. J Pharmacol Exp Ther 313, 594-603 (2005).
46. von Engelhardt, J. et al. CKAMP44: a brain-specific protein attenuating shortterm synaptic plasticity in the dentate gyrus. Science 327, 1518-1522 (2010).
47. Wang, L. Y. & MacDonald, J. F. Modulation by magnesium of the affinity of NMDA receptors for glycine in murine hippocampal neurones. J Physiol 486 (Pt 1), 83-95 (1995).
48. Nozaki, C. et al. Zinc alleviates pain through high-affinity binding to the NMDA receptor NR2A subunit. Nat Neurosci 14, 1017-1022 (2011).